Dr. Kumar on Implications of BELLINI Trial in Relapsed/Refractory Multiple Myeloma
October 31st 2019Shaji K. Kumar, MD, discusses the takeaways from the phase III BELLINI trial which tested venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Dr. Bekaii-Saab on the Rationale to Explore Tucatinib/Trastuzumab in HER2-Overexpressing mCRC
October 23rd 2019Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.
Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC
October 15th 2019Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.
Dr. Bekaii-Saab on the Rationale to Evaluate Atezolizumab/Bevacizumab in MSS mCRC
October 5th 2019Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the rationale to evaluate atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Dr. Goetz on Treatment Beyond Progression on CDK4/6 Inhibitors in HR+ Breast Cancer
August 23rd 2019Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses treatment beyond progression on CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.
Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast Cancer
August 16th 2019Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the treatment landscape of estrogen receptor (ER)–positive breast cancer and advances made within the last 5 years.